Graph Neural Networks Drug Target Prediction

Graph Neural Networks for Protein-Drug Binding Affinity Prediction

This research investigates how graph neural networks can model molecular interactions by representing proteins and ligands as interconnected graph structures to predict binding affinities. The work advances computational drug discovery by enabling rapid, accurate identification of candidate compounds for disease targets without expensive wet-lab screening.

Heterogeneous Graph Learning for Multi-Modal Drug Repurposing Networks

This research explores heterogeneous graph neural networks that integrate diverse biological data types including protein interactions, chemical structures, disease phenotypes, and clinical outcomes into unified predictive models. The approach generates novel drug-disease associations by discovering hidden patterns across multiple biological domains simultaneously.

Message Passing Neural Networks for Target-Agnostic Drug Mechanism Discovery

This research develops message-passing graph neural architectures that propagate chemical and biological information across drug-target-pathway networks to uncover novel mechanisms of action. The investigation produces mechanistic insights into how existing drugs interact with unexpected biological targets relevant to new therapeutic indications.

Attention-Based Graph Transformers for Drug-Disease Similarity Learning

This research applies graph transformer architectures with attention mechanisms to learn distributed representations of drugs and diseases in high-dimensional molecular space. The advancement enables identification of structurally dissimilar drugs with comparable therapeutic profiles for rapid repurposing hypothesis generation.

Temporal Graph Neural Networks for Drug Response Evolution Tracking

This research develops temporal graph neural networks that model dynamic changes in drug-target interactions, resistance mechanisms, and patient response trajectories over time. The study reveals time-dependent drug efficacy patterns and optimal repurposing windows for therapeutic intervention in disease progression.

Explainable Graph Neural Networks for Transparent Target Prioritization

This research creates interpretable graph neural network architectures that decompose drug repurposing predictions into human-readable molecular substructures and biological pathways contributing to target selection. The work establishes scientific credibility for computational predictions through mechanistic transparency valued by pharmaceutical researchers.

Graph Autoencoders for Novel Drug-Target Space Exploration

This research employs graph autoencoder models to learn compressed latent representations of drug-target networks and generate synthetic compounds with predicted novel binding profiles. The approach discovers underexplored regions of chemical space where existing drugs may possess unexpected off-target activities with therapeutic value.

Multi-Relational Graph Neural Networks for Polypharmacology Target Mapping

This research develops multi-relational graph neural networks that simultaneously model diverse interaction types including direct binding, pathway crosstalk, and side-effect relationships for drugs. The investigation maps polypharmacological profiles enabling strategic repurposing toward complex diseases requiring multi-target interventions.

Contrastive Learning on Molecular Graphs for Cross-Indication Drug Transfer

This research applies contrastive learning frameworks to graph neural networks for learning invariant drug representations transferable across disease indications with similar molecular mechanisms. The approach accelerates discovery of drugs effective against disease phenotypes structurally or functionally distinct from original therapeutic targets.

Knowledge Graph Embeddings with Graph Neural Networks for Drug Indication Transfer

This research combines knowledge graph embedding techniques with graph neural network architectures to predict new therapeutic indications by leveraging vast biomedical literature and experimental databases. The integration produces evidence-ranked drug repurposing candidates supported by multi-source biological knowledge for hypothesis validation.